Represents Grant table in the DB

GET /v1/grants?page%5Bnumber%5D=1392&sort=-funder_divisions
HTTP 200 OK
Allow: GET, POST, HEAD, OPTIONS
Content-Type: application/vnd.api+json
Vary: Accept

{
    "links": {
        "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder_divisions",
        "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=-funder_divisions",
        "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=-funder_divisions",
        "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=-funder_divisions"
    },
    "data": [
        {
            "type": "Grant",
            "id": "15592",
            "attributes": {
                "award_id": "5IK6RX004809-02",
                "title": "RR&D Research Career Scientist Award Application",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2023-10-01",
                "end_date": "2028-09-30",
                "award_amount": null,
                "principal_investigator": {
                    "id": 28149,
                    "first_name": "Melissa A",
                    "last_name": "Kacena",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1636,
                    "ror": "",
                    "name": "RLR VA MEDICAL CENTER",
                    "address": "",
                    "city": "",
                    "state": "IN",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "A primary goal of my research program is to identify and test new therapeutic approaches to improve and accelerate fracture healing and overall patient outcomes. This includes improving weightbearing, locomotion, and activity, while decreasing the associated pain and inflammation. In my current VA funded studies, we are seeking to determine how Sirtuin-1 (Sirt1, an NAD+ class III histone deacetylase) activators alter fracture healing outcomes. We began examining Sirt1 as a target as our preliminary data showed that mRNA levels of Sirt1 are robustly elevated during fracture healing. We knew that fracture healing is impaired with age, bone loss, inflammation, and with neurodegeneration, and realized that Sirt1 improves all of these conditions.  Our ultimate goal is to improve fracture outcomes for Veterans and civilians. Thus, an important objective of our studies is to translate our findings to the clinic. With this in mind, we have successfully obtained one patent (16/392,246, April 23, 2019) and have applied for a second patent (63/153,297, February 24, 2021). The second patent application includes Drs. Philip Low and Jeffery Nielsen as co-Inventors (also collaborators on our current VA Merit award) who are medicinal chemists. With their assistance, we developed a new fracture targeted SRT1720 drug, which we are investigating in our VA Merit studies. Notably, 15 drugs stemming from Dr. Low’s research have entered human clinical trials. Importantly, we have also developed an important collaboration with VA investigator, Dr. Fletcher White, a neuroscientist with expertise in locomotion, pain, and inflammation analyses. Together, our team will investigate whether pharmacological activation of Sirt1 by fracture targeting SRT1720 allows for improved fracture healing, while reducing pain behaviors.  Additional studies funded by 3 PI/mPI NIH R01s and internal, foundation and training awards focus on the bone marrow microenvironment and its regulation of fracture healing, bone mass, and hematopoiesis. The goal of NIH R01 AG060621 is to understand the mechanisms by which angiogeneic therapies can improve aged fracture healing. The goal of NIH R01 DK118782 is to understand the mechanisms by which osteomacs and megakaryocytes regulate hematopoiesis. The goal of NIH R01 DK108342 is to examine how CD166 regulates hematopoietic stem cell function and the hematopoietic niche. Pilot funds and an NIH F31 AG077931 PhD fellowship fund investigations on the bone loss following infection with SARS-CoV-2. These studies have significant implications to aiding in rehabilitation of Veterans and improving their quality of life.  My lab has been very productive with 52 data driven manuscripts and 17 review articles/chapters published since 2018. During this time, I have given 21 lectures at national/international venues, including an invitation as an Esteemed Speaker for the Australian and New Zealand Bone and Mineral Society meeting in 2019. Continuous extramural funding for the past 15 years has enabled us to achieve our research goals.  I have also been extensively involved with mentoring junior faculty, post-doctoral fellows, clinical residents, graduate students, medical students, undergraduate students, and high school students for more than 20 years (>100 mentees). I have served on numerous grant review committees at national and international levels including as a permanent member of the NIH, Skeletal Biology Development and Disease (SBDD) Study Section and will begin reviewing VA Merit Awards in 2023. I have served/am serving on the Editorial Review Board for the Journal of Orthopaedic Research and JBMR Plus; as a Guest Editor for Frontiers in Endocrinology; section editor for Current Osteoporosis Reports; and am Editor-in-Chief for Current Osteoporosis Reports. I have also been nominated and elected into leadership roles within several institutions/societies. Currently, I am the Vice Chair for Research for the Department of Orthopaedic Surgery at IUSM and am an elected member of the Council for the American Society for Bone and Mineral Research. These research, mentoring, leadership, and service activities highlight the significance and recognition of my research activities to the musculoskeletal field.",
                "keywords": [
                    "2019-nCoV",
                    "ALCAM gene",
                    "Acceleration",
                    "Accidents",
                    "Accounting",
                    "Age",
                    "Aging",
                    "American",
                    "American Society of Hematology",
                    "Amputation",
                    "Analgesics",
                    "Animal Model",
                    "Applications Grants",
                    "Award",
                    "Biography",
                    "Biology",
                    "Blood",
                    "Bone Marrow",
                    "Bone Regeneration",
                    "Book Chapters",
                    "Caring",
                    "Cells",
                    "Clinic",
                    "Clinical",
                    "Clinical Trials",
                    "Collaborations",
                    "Data",
                    "Defect",
                    "Department of Defense",
                    "Development",
                    "Devices",
                    "Diabetes Mellitus",
                    "Disease",
                    "Doctor of Philosophy",
                    "Drug Targeting",
                    "Endocrinology",
                    "Equipment",
                    "Extramural Activities",
                    "Faculty",
                    "Family suidae",
                    "Fellowship",
                    "Foundations",
                    "Fracture",
                    "Funding",
                    "Future",
                    "Goals",
                    "Grant",
                    "Grant Review",
                    "Growth Factor",
                    "Health",
                    "Health Care",
                    "Hematopoiesis",
                    "Hematopoietic",
                    "Hematopoietic stem cells",
                    "High Fat Diet",
                    "High School Student",
                    "Histone Deacetylase",
                    "Human",
                    "Impairment",
                    "Indiana",
                    "Infection",
                    "Inflammation",
                    "Injury",
                    "Institution",
                    "Intellectual Property",
                    "International",
                    "Investigation",
                    "Journals",
                    "Leadership",
                    "Legal patent",
                    "Limb structure",
                    "Locomotion",
                    "Manuscripts",
                    "Medical",
                    "Medical Students",
                    "Medicine",
                    "Megakaryocytes",
                    "Mentors",
                    "Messenger RNA",
                    "Military Personnel",
                    "Minerals",
                    "Modeling",
                    "Modernization",
                    "Mus",
                    "Musculoskeletal",
                    "Natural regeneration",
                    "Nerve Degeneration",
                    "New Zealand",
                    "Non-Insulin-Dependent Diabetes Mellitus",
                    "Obesity",
                    "Occupational Therapy",
                    "Open Fractures",
                    "Operative Surgical Procedures",
                    "Opioid",
                    "Orthopedic Surgery",
                    "Orthopedics",
                    "Osteoporosis",
                    "Outcome",
                    "Overdose",
                    "Overweight",
                    "Pain",
                    "Pain management",
                    "Patient-Focused Outcomes",
                    "Peer Review",
                    "Pharmaceutical Preparations",
                    "Population Projection",
                    "Postdoctoral Fellow",
                    "Productivity",
                    "Prosthesis",
                    "Publications",
                    "Publishing",
                    "Quality of life",
                    "Recovery",
                    "Regimen",
                    "Regulation",
                    "Rehabilitation therapy",
                    "Reporting",
                    "Research",
                    "Research Activity",
                    "Research Personnel",
                    "Review Committee",
                    "Risk",
                    "Roentgen Rays",
                    "Role",
                    "SIRT1 gene",
                    "Scientist",
                    "Seminal",
                    "Services",
                    "Sheep",
                    "Side",
                    "Site",
                    "Societies",
                    "Soldier",
                    "Space Flight",
                    "Study Section",
                    "Surgeon",
                    "System",
                    "Testing",
                    "Therapeutic Agents",
                    "Thrombopoietin",
                    "Time",
                    "Tissues",
                    "Training",
                    "Translating",
                    "Trauma",
                    "United States National Institutes of Health",
                    "Universities",
                    "Veterans",
                    "War",
                    "Weight-Bearing state",
                    "Wheelchairs",
                    "Work",
                    "active duty",
                    "aged",
                    "angiogenesis",
                    "animal efficacy",
                    "bone",
                    "bone fracture repair",
                    "bone healing",
                    "bone"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "15593",
            "attributes": {
                "award_id": "5IK6HX003768-02",
                "title": "HSR&D Research Career Scientist Award",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2023-10-01",
                "end_date": "2028-09-30",
                "award_amount": null,
                "principal_investigator": {
                    "id": 23769,
                    "first_name": "Marianne",
                    "last_name": "Matthias",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 1636,
                            "ror": "",
                            "name": "RLR VA MEDICAL CENTER",
                            "address": "",
                            "city": "",
                            "state": "IN",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1636,
                    "ror": "",
                    "name": "RLR VA MEDICAL CENTER",
                    "address": "",
                    "city": "",
                    "state": "IN",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "My research focuses on understanding and improving chronic pain management for Veterans by leveraging my expertise in health communication, patient engagement, and relationship-centered care. Over the past 14 years, my work has developed from observational to interventional, steadily increasing the impact of my scholarship on Veterans’ care. My research has helped to advance our understanding of how communication shapes healthcare experiences and Veterans’ pain management. Early observational work led to insights into the role of the patient-provider relationship and social support in pain self-management, treatment decision- making, and opioid management, including opioid tapering. I have successfully built upon these findings with each new project, which has led to the design and testing of interventions to improve pain management for Veterans. These interventions have included developing and testing a peer-supported pain self-management program, a coaching program designed to increase patient activation for Black Veterans with chronic pain to help address racialized disparities in pain management, and a shared decision-making intervention to overcome patient-level barriers to use of and adherence to evidence-based nonpharmacologic pain treatments. Beyond developing and testing interventions, I am also moving toward implementation in an effort to broaden my impact and improve care for Veterans. My health equity study, COOPERATE, significantly increased patient activation and communication self-efficacy, while producing other positive outcomes for Black Veterans. In light of these positive results I will be exploring avenues for implementation through our operational partners as well as likely submitting a proposal for a Hybrid Type 2 multi-site effectiveness/implementation study, to further test COOPERATE and prepare for system-wide implementation. COOPERATE represents an important path to achieving health equity for Black Veterans with chronic pain and as such, also represents the increasing impact of my research. My newly-funded study, OPTIONS, also has direct relevance for Veteran care and impact. OPTIONS reflects VA’s priorities of reducing reliance on opioids and increasing use of multimodal care, including evidence-based complementary and integrative therapies and other nonpharmacologic approaches to chronic pain. As such, I have partnered with the VA National Pain Management, Opioid Safety, and Prescription Drug Monitoring Program Office and the Office of Patient- Centered Care and Cultural Transformation, and, assuming positive results, these partnerships will help increase the project’s impact by facilitating VA-wide dissemination and, ultimately, implementation. These examples reflect the evolution of my work from early observational studies to intervention studies, which will ultimately lead to system-wide implementation and greater impact on Veterans’ pain care. The other study I am currently leading as co-PI, CIPHER, is focused on understanding effects of COVID-19-related disruptions in pain care on Veterans with chronic low-back pain, with particular emphasis on disruptions to nonpharmacologic care, which can be more difficult to deliver via telehealth. Using a mixed-methods design with VA administrative data and qualitative interviews with clinicians and Veterans purposefully sampled from the administrative data, we are partnering with the VA National Pain Management Office to understand changes in care and, ultimately, apply these lessons to improving pain care for Veterans.",
                "keywords": [
                    "Academy",
                    "Address",
                    "Adherence",
                    "Affect",
                    "American",
                    "Anxiety",
                    "Area",
                    "Award",
                    "Black race",
                    "COVID-19 impact",
                    "Caring",
                    "Categories",
                    "Chronic low back pain",
                    "Clinic Visits",
                    "Clinical",
                    "Clinical Sciences",
                    "Clinical Trials",
                    "Communication",
                    "Compassion",
                    "Complementary therapies",
                    "Conceptions",
                    "Conflict (Psychology)",
                    "Counseling",
                    "Data",
                    "Decision Making",
                    "European",
                    "Evolution",
                    "Follow-Up Studies",
                    "Fostering",
                    "Funding",
                    "Goals",
                    "Health",
                    "Health Care",
                    "Health Services",
                    "Homogeneously Staining Region",
                    "Hybrids",
                    "Integrative Therapy",
                    "Internal Medicine",
                    "International",
                    "Intervention",
                    "Intervention Studies",
                    "Interview",
                    "Journals",
                    "K-Series Research Career Programs",
                    "Learning",
                    "Light",
                    "Medicine",
                    "Mental Depression",
                    "Methods",
                    "New South Wales",
                    "New Zealand",
                    "Nonpharmacologic Therapy",
                    "Observational Study",
                    "Office Management",
                    "Opioid",
                    "Outcome",
                    "Pain",
                    "Pain management",
                    "Participant",
                    "Patient Education",
                    "Patient-Centered Care",
                    "Patients",
                    "Peer Review",
                    "Personal Satisfaction",
                    "Physicians",
                    "Play",
                    "Policies",
                    "Positioning Attribute",
                    "Postdoctoral Fellow",
                    "Provider",
                    "Public Health",
                    "Publications",
                    "Publishing",
                    "Quality of life",
                    "Recommendation",
                    "Research",
                    "Research Personnel",
                    "Role",
                    "Safety",
                    "Sampling",
                    "Scholarship",
                    "Scientist",
                    "Self Efficacy",
                    "Self Management",
                    "Services",
                    "Shapes",
                    "Site",
                    "Social support",
                    "Societies",
                    "System",
                    "Testing",
                    "Time",
                    "Trust",
                    "Uncertainty",
                    "United States National Institutes of Health",
                    "Veterans",
                    "Work",
                    "career",
                    "chronic pain",
                    "chronic pain management",
                    "college",
                    "coping",
                    "design",
                    "effective intervention",
                    "effectiveness/implementation study",
                    "evidence base",
                    "experience",
                    "health care disparity",
                    "health communication",
                    "health equity",
                    "improved",
                    "indexing",
                    "insight",
                    "multi-site trial",
                    "multimodality",
                    "novel",
                    "novel strategies",
                    "opioid tapering",
                    "pain self-management",
                    "patient engagement",
                    "patient-clinician communication",
                    "patient-level barriers",
                    "peer support",
                    "prescription monitoring program",
                    "programs",
                    "racial disparity",
                    "randomized trial",
                    "self-management program",
                    "shared decision making",
                    "telehealth",
                    "therapy design",
                    "tool"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "15594",
            "attributes": {
                "award_id": "5I01BX006270-02",
                "title": "SARS-CoV-2 and Innate Immunity: Mechanisms of Resistance to Human Interferons",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2023-10-01",
                "end_date": "2027-09-30",
                "award_amount": null,
                "principal_investigator": {
                    "id": 28150,
                    "first_name": "Eric M.",
                    "last_name": "Poeschla",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1828,
                    "ror": "https://ror.org/04d7ez939",
                    "name": "VA Eastern Colorado Health Care System",
                    "address": "",
                    "city": "",
                    "state": "CO",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "SARS-CoV-2 emerged in late 2019, with much evidence tracing the initial human spillover to a market with extensive human-animal contact. As the coronavirus spread in its new host species, multiple variants of concern representing distinct genetic lineages appeared and propagated globally. Ongoing viral evolution has increased transmission, and also evasion of neutralizing antibodies (adaptive arm of the immune system). Hence, many important studies have deservedly focused on dissecting consequences of Spike protein mutations in different emerged variants. However, mutations have also been detected in viral genes other than Spike, and several of these genes are linked to antagonism of innate immune responses. We provide detailed evidence that compared to ancestral or early SARS-CoV-2 isolates, the five major variants of concern so far (alpha, beta, gamma, delta and omicron) have become more resistant to multiple human interferons that included the 12 IFNα subtypes, IFNβ, IFNω and 3 IFNλ subtypes1. The underlying mechanisms for these IFN resistance phenotypes are unclear and, paralleling the four decades it has taken to understand innate immune evasions mediated by the proteins encoded by the nine genes of HIV-1, a full picture for SARS-CoV-2 will require sustained investigation over time. However, in both the short and long terms, the scientific and medical impacts of characterizing resistance of this newly emerged coronavirus mechanistically can be highly significant, for not only the current pandemic but potentially also for future sarbecovirus spillover events. We thus propose to build on our ample published1 and unpublished preliminary data and accumulated experience to track the evolution of SARS-CoV-2 IFN resistance during the course of the COVID-19 pandemic and to determine virus mutations and effector mechanisms involved. As interferon responses can regulate virus levels during the critical acute phase of infection, these studies will have implications for understanding SARS-CoV-2 transmission and pathogenesis that may inform therapeutic strategies not only against SARS- CoV-2 but also future emerging viruses.",
                "keywords": [
                    "2019-nCoV",
                    "A549",
                    "Acute",
                    "Adrenal Cortex Hormones",
                    "Alveolar",
                    "Animal Model",
                    "Animals",
                    "Antibodies",
                    "Attention",
                    "Automobile Driving",
                    "CD4 Positive T Lymphocytes",
                    "COVID-19",
                    "COVID-19 mortality",
                    "COVID-19 pandemic",
                    "COVID-19 patient",
                    "Cell Line",
                    "Cells",
                    "Cessation of life",
                    "Chronic",
                    "Clinical Trials",
                    "Collaborations",
                    "Coronavirus",
                    "Data",
                    "Development",
                    "Early treatment",
                    "Employee",
                    "Epidemiology",
                    "Epithelial Cells",
                    "Evolution",
                    "Family",
                    "Funding",
                    "Future",
                    "Genes",
                    "Genetic",
                    "Grant",
                    "HIV-1",
                    "Hospitalization",
                    "Human",
                    "Human Genome",
                    "IFNAR1 gene",
                    "Immune",
                    "Immune Evasion",
                    "Immune system",
                    "Immunity",
                    "In Vitro",
                    "Infection",
                    "Inflammation",
                    "Innate Immune Response",
                    "Interferon Type I",
                    "Interferon Type II",
                    "Interferon-α",
                    "Interferons",
                    "Investigation",
                    "Laboratories",
                    "Link",
                    "Long-term disability",
                    "Lower respiratory tract structure",
                    "Lung",
                    "Marketing",
                    "Mediating",
                    "Medical",
                    "Modeling",
                    "Mucous Membrane",
                    "Mutation",
                    "Natural Immunity",
                    "Nucleocapsid",
                    "Pathogenesis",
                    "Persons",
                    "Phase",
                    "Phenotype",
                    "Physiological",
                    "Probability",
                    "Process",
                    "Proteins",
                    "Publishing",
                    "Records",
                    "Research Personnel",
                    "Resistance",
                    "Resistance development",
                    "Risk",
                    "Role",
                    "Route",
                    "SARS-CoV-2 B.1.1.529",
                    "SARS-CoV-2 B.1.1.7",
                    "SARS-CoV-2 B.1.351",
                    "SARS-CoV-2 B.1.617.2",
                    "SARS-CoV-2 inhibitor",
                    "SARS-CoV-2 transmission",
                    "SARS-CoV-2 variant",
                    "Sampling",
                    "Sarbecovirus",
                    "Science",
                    "Signal Transduction",
                    "Structure of parenchyma of lung",
                    "System",
                    "T-Lymphocyte",
                    "Testing",
                    "Therapeutic",
                    "Therapeutic Agents",
                    "Time",
                    "Upper respiratory tract",
                    "Vaccinee",
                    "Vaccines",
                    "Variant",
                    "Veterans",
                    "Viral",
                    "Viral Drug Resistance",
                    "Viral Genes",
                    "Viral Load result",
                    "Viral Physiology",
                    "Viral Proteins",
                    "Virus",
                    "Virus Replication",
                    "Work",
                    "Writing",
                    "acute COVID-19",
                    "adaptive immune response",
                    "antagonist",
                    "arm",
                    "breakthrough infection",
                    "cellular targeting",
                    "comparative",
                    "current pandemic",
                    "design",
                    "emerging virus",
                    "experience",
                    "follow-up",
                    "insight",
                    "mucosal HIV infection",
                    "neutralizing antibody",
                    "novel",
                    "novel coronavirus",
                    "overexpression",
                    "pandemic disease",
                    "pandemic potential",
                    "pandemic virus",
                    "protein function",
                    "receptor",
                    "resistance mechanism",
                    "response",
                    "reverse genetics",
                    "severe COVID-19",
                    "spillover event",
                    "therapy development",
                    "tissue culture",
                    "transcriptome",
                    "transmission process",
                    "variants of concern",
                    "virus host interaction"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "15595",
            "attributes": {
                "award_id": "5I01BX004686-02",
                "title": "Calcium release-activated calcium (CRAC) channels in experimental traumatic brain injury",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2023-10-01",
                "end_date": "2027-09-30",
                "award_amount": null,
                "principal_investigator": {
                    "id": 28673,
                    "first_name": "Midori A",
                    "last_name": "Yenari",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1522,
                    "ror": "",
                    "name": "VETERANS AFFAIRS MED CTR SAN FRANCISCO",
                    "address": "",
                    "city": "",
                    "state": "CA",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "This project will explore calcium-release-activated calcium channels (CRAC) as a potential therapeutic target in a laboratory model of traumatic brain injury (TBI). TBI is a common problem in the Veteran and civilian populations but definitive treatments are few. Microglia are the brain’s resident immune cell, and many studies have now shown that when activated, they contribute negatively to neurological outcome. Thus, strategies to inhibit microglial functions could prove therapeutic. Recent work has focused on the role of CRAC channels in inflammatory cells such as T cells, mast cells and neutrophils, and other inflammatory conditions such as autoimmune disease and acute pancreatitis; however, very little work has been published on CRAC channels as they pertain to microglia or inflammation in the brain. Past work has focused on calcineurin inhibitors such as cyclosporine A and FK 506 which act downstream of the CRAC channel, but have many off target effects and clinical toxicities which limit their use. These CRAC channel inhibitors are already being studied at the clinical level for other indications, and do not appear to have the same toxicities as the CNIs. In fact, a similar inhibitor produced by the same company was recently shown to improve outcome from severe COVID-19 pneumonia following infection with the SARS-CoV-2 virus, and was well tolerated in this patient population. Prior work in our lab showed that these specific CRAC channel inhibitors block microglial activation and that at least one of these inhibitors protects the brain from experimental TBI. This project will study CRAC channel inhibitors in a model of TBI to further define the conditions where neuroprotection may be observed. The first Aim will determine the more protective of two such novel CRAC channel inhibitors, and determine the optimal dosing required for maximum neurological benefit. This aim will also validate the specificity of the inhibitors and the expected mechanism of action of downstream calcium and inflammatory signaling. The second aim will then determine whether treatment can be delayed by hours and still show improvement in neurological outcomes. The third aim will then use the optimal dose and dosing regimen determined from the first two aims to see if any benefit is long lasting. In vivo experiments will include studies in female animals as well as comparing these novel, specific inhibitors to currently available, but less specific inhibitors.",
                "keywords": [
                    "2019-nCoV",
                    "Acute",
                    "Acute Brain Injuries",
                    "Affect",
                    "Animals",
                    "Area",
                    "Autoimmune Diseases",
                    "Binding",
                    "Biological Assay",
                    "Biotechnology",
                    "Brain",
                    "Brain Injuries",
                    "COVID-19 pneumonia",
                    "Calcineurin",
                    "Calcineurin Pathway",
                    "Calcineurin inhibitor",
                    "Calcium",
                    "Calcium Channel",
                    "Cells",
                    "Clinical",
                    "Collaborations",
                    "Cyclosporine",
                    "Cytoprotection",
                    "Dose",
                    "Experimental Models",
                    "FK506",
                    "Female",
                    "Hour",
                    "Human",
                    "Immune",
                    "Immune response",
                    "Immune signaling",
                    "Immunosuppression",
                    "In Vitro",
                    "Infection",
                    "Inflammation",
                    "Inflammatory",
                    "Inflammatory Response",
                    "Injury",
                    "Laboratories",
                    "Length",
                    "Mediating",
                    "Microglia",
                    "Modeling",
                    "Mus",
                    "Nervous System Trauma",
                    "Neurologic",
                    "Neurological outcome",
                    "Outcome",
                    "Pathway interactions",
                    "Plasma",
                    "Population",
                    "Publishing",
                    "Pulmonary Inflammation",
                    "Regimen",
                    "Regulation",
                    "Role",
                    "Signal Transduction",
                    "Site",
                    "Source",
                    "Specificity",
                    "Stroke",
                    "T-Lymphocyte",
                    "Tacrolimus",
                    "Testing",
                    "Therapeutic",
                    "Toxic effect",
                    "Translations",
                    "Traumatic Brain Injury",
                    "Upregulation",
                    "Veterans",
                    "Virus",
                    "Woman",
                    "Women&apos",
                    "s study",
                    "Work",
                    "acute COVID-19",
                    "acute pancreatitis",
                    "brain tissue",
                    "cohort",
                    "effective therapy",
                    "experimental study",
                    "glial activation",
                    "immunoreaction",
                    "improved",
                    "improved outcome",
                    "in vivo",
                    "inhibitor",
                    "knock-down",
                    "male",
                    "mast cell",
                    "men",
                    "neuroprotection",
                    "neutrophil",
                    "novel",
                    "patient population",
                    "prevent",
                    "response",
                    "severe COVID-19",
                    "side effect",
                    "small molecule inhibitor",
                    "stroke model",
                    "therapeutic target"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "15674",
            "attributes": {
                "award_id": "1I01BX006818-01",
                "title": "Regulation of T cell immunity",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2025-04-01",
                "end_date": "2029-03-31",
                "award_amount": null,
                "principal_investigator": {
                    "id": 32517,
                    "first_name": "John T",
                    "last_name": "Chang",
                    "orcid": "",
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 2485,
                    "ror": "https://ror.org/00znqwq11",
                    "name": "VA San Diego Healthcare System",
                    "address": "",
                    "city": "",
                    "state": "CA",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Background and Innovation: Mortality from infectious diseases remains the second leading cause of death worldwide, a fact highlighted by 4 years of a global pandemic, making the understanding of host responses, development of new vaccines, and improving existing vaccines important priorities of biomedical research. Memory T cells mediate protection from reinfection with previously encountered pathogens, and a large number of these cells, termed tissue-resident memory cells (TRM), do not recirculate throughout the body, reside within tissues, and provide essential sentinel protection at body surfaces. Using a murine infection model that is well established in the field for studying CD8 TRM, this application will investigate the context- and tissue-specific roles of the transcription factor Foxo1. Conceptual innovations include the study of Foxo1, the role of which is poorly understood in TRM biology. Technical innovations include the use of numerous cutting- edge approaches, including Cellular Indexing of Transcriptomes and Epitopes (CITE-seq) which enables proteomic and transcriptomic (scRNA-seq) analyses in the same single-cells, to identify consequences of Foxo1-deficiency in TRM. Bioinformatic innovations include the application of Taiji, a state-of-the-art bioinformatic analysis algorithm integrating transcriptomic and epigenomic data, to reveal Foxo1-transcription factor networks and identify putative regulatory factors and pathways controlled by Foxo1. Significance and Impact to Veterans Healthcare: Infectious diseases have a substantial public health and economic burden on the Veteran population. These include diseases for which we have vaccines, such as SARS-CoV-2 and influenza, as well as diseases that we do not yet have vaccines for, such as Hepatitis C (HCV) and HIV. A major gap in knowledge is that current vaccines generate neutralizing antibodies but do not generate a robust memory T cell response, including TRM, which are crucial for optimal protection at barrier surfaces. Another gap in knowledge is a comprehensive molecular understanding of the tissue-specific requirements for the generation and persistence of TRM, which will be addressed by this project. This research will address the VHA/ORD research priority of exploring fundamental biologic principles in pre-clinical models with the ultimate goal of improving the well-being of the nation’s Veterans specifically in the area of infectious diseases. Path to translation/implementation: Current vaccination regimens aim to generate protective antibodies but do not generate TRM. A detailed understanding of regulatory programs and transcriptional networks that govern T cell adaptation to tissues and barrier sites must be gained in order to provide the foundation and rational scientific basis to develop “tissue-tailored” immune responses. In this way, immune cells that promote or regulate inflammation can be transcriptionally engineered for trafficking to, retention in, and function within a particular tissue. Next steps to move this research along the translational pathway will involve testing whether modulation of Foxo1-mediated pathways enhances vaccine-generated immune memory.",
                "keywords": [
                    "2019-nCoV",
                    "Address",
                    "Adoptive Transfer",
                    "Algorithmic Analysis",
                    "Antibodies",
                    "Area",
                    "Bioinformatics",
                    "Biological",
                    "Biology",
                    "Biomedical Research",
                    "Blood",
                    "Body Surface",
                    "CD8-Positive T-Lymphocytes",
                    "CD8B1 gene",
                    "CRISPR/Cas technology",
                    "Categories",
                    "Cause of Death",
                    "Cell Differentiation process",
                    "Cells",
                    "Cellular Indexing of Transcriptomes and Epitopes by Sequencing",
                    "Cellular biology",
                    "Circulation",
                    "Colon",
                    "Communicable Diseases",
                    "Computer Analysis",
                    "Data",
                    "Development",
                    "Disease",
                    "Economic Burden",
                    "Engineering",
                    "Epitopes",
                    "Exhibits",
                    "FOXO1A gene",
                    "Foundations",
                    "Generations",
                    "Genetic",
                    "Genetic Transcription",
                    "Goals",
                    "HIV/HCV",
                    "Health",
                    "Health Care",
                    "Homologous Gene",
                    "Human",
                    "Immune",
                    "Immune response",
                    "Immunity",
                    "Immunologic Memory",
                    "Infection",
                    "Infectious Skin Diseases",
                    "Inflammation",
                    "Influenza",
                    "Integrins",
                    "Kidney",
                    "Knowledge",
                    "Liver",
                    "Lymphocytic choriomeningitis virus",
                    "Lymphoid Tissue",
                    "Maintenance",
                    "Mediating",
                    "Memory",
                    "Modeling",
                    "Molecular",
                    "Morbidity - disease rate",
                    "Mucous Membrane",
                    "Mus",
                    "Neoplasm Metastasis",
                    "Organ",
                    "Pathogenesis",
                    "Pathway interactions",
                    "Personal Satisfaction",
                    "Play",
                    "Population",
                    "Pre-Clinical Model",
                    "Proteins",
                    "Proteomics",
                    "Public Health",
                    "RUNX3 gene",
                    "Regimen",
                    "Repression",
                    "Research",
                    "Research Priority",
                    "Residencies",
                    "Respiratory Mucosa",
                    "Role",
                    "Salivary Glands",
                    "Sentinel",
                    "Site",
                    "Skin",
                    "Small Intestines",
                    "Sphingosine-1-Phosphate Receptor",
                    "Surface",
                    "System",
                    "T cell regulation",
                    "T cell response",
                    "T memory cell",
                    "T-Cell Receptor",
                    "T-Lymphocyte",
                    "Tai Ji",
                    "Tamoxifen",
                    "Testing",
                    "Therapeutic",
                    "Tissue Differentiation",
                    "Tissues",
                    "Transcription Repressor",
                    "Transgenic Organisms",
                    "Translations",
                    "Vaccination",
                    "Vaccines",
                    "Veterans",
                    "adaptive immunity",
                    "chemokine receptor",
                    "design",
                    "epigenomics",
                    "field study",
                    "first responder",
                    "improved",
                    "indexing",
                    "innovation",
                    "military veteran",
                    "mortality",
                    "neutralizing antibody",
                    "novel vaccines",
                    "pandemic disease",
                    "pathogen",
                    "pathogenic microbe",
                    "programs",
                    "response",
                    "trafficking",
                    "transcription factor",
                    "transcriptome",
                    "transcriptomics",
                    "tumor growth"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "15677",
            "attributes": {
                "award_id": "1I21BX007163-01",
                "title": "Development of 12-Lipoxygenase Inhibitors for diabetes treatment.",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2025-04-01",
                "end_date": "2027-03-31",
                "award_amount": null,
                "principal_investigator": {
                    "id": 32522,
                    "first_name": "JERRY L.",
                    "last_name": "NADLER",
                    "orcid": "",
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 2157,
                    "ror": "",
                    "name": "VA NORTHERN CALIFORNIA HEALTH CARE SYS",
                    "address": "",
                    "city": "",
                    "state": "CA",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Approximately 25% of US Veterans have diabetes and the annual mortality rate due to diabetes in Veterans is almost double of the rate in Veterans without diabetes. The presence of diabetes in the Veteran population is an important cause of disability due to complications such as cardiovascular disease, neuropathy, retinopathy, and kidney disease. Recent studies have indicated higher rates of new onset diabetes in Veterans who have had COVID-19 and analysis of Veterans using the Million Veteran Database indicate a growing identification of new onset type 1 diabetes (T1D) in adults. Almost half of the newly diagnosed cases of T1D are adults and there is an unmet medical need to identify treatments to prevent or halt progression of the disease. 12-lipoxygenase (12-LOX) is a lipid-generating enzyme produced by various sites including pancreatic islet beta cells. 12- LOX expression is elevated in obesity, Type 2 diabetes ( T2D) and T1D. We showed that 12-LOX protein is increased in islets of auto-antibody-positive and Type 1 and Type 2 individuals. 12-LOX products are highly pro-inflammatory and reduce pancreatic beta cell function and viability. 12-LOX lipids lead to oxidative and endoplasmic reticulum stress and macrophage activation. Genetic deletion of 12-LOX in mouse models improves insulin signaling and prevents T1D development. We earlier discovered a highly selective 12-LOX inhibitor, ML-355, through a comprehensive screening, followed by iterative medicinal chemistry optimization. ML-355 has been licensed and pre-clinical and phase 1 safety testing has been successfully completed and found to be safe. ML-355 is in a phase 2 clinical trial for intravenous administration for a hematologic indication as the inhibitor is not sufficiently orally bio-available for chronic diabetes use. We recently discovered a new 12-LOX inhibitor, Slug001, which manifests increased potency both in vitro and in rescuing inflamed human islet cells, relative to ML355. We propose to explore this novel structural space with a suite of modifications of Slug001, guided by our computational modeling of ML355 docking. The goal in Aim 1 is to derivatize Slug001 and fill the active site cavity more efficiently so that the inhibitor potency can be increased more than its current 7-fold improvement relative to ML355 and have improved oral bioavailability. The docking model will greatly enhance the identification of promising new inhibitors. Of the six Slug001 lead derivatives, we have already synthesized several and shown that Slug002 is as potent as Slug001 but has better solubility. The completed studies will generate novel inhibitors and a new VA patent. In Aim 1 of the proposal, we will synthesize the new molecules and measure their potency and selectivity. Established methods, comparing potency with docking scores, will allow us to quickly design these derivatives, increase their potency and then subject them to our human diabetic cellular assays established in Aim 2. The derivatives of Slug001 will be screened by the Holman laboratory against the LOX isozymes (5-LOX, 12-LOX, 15-LOX-1, 15-LOX-2) to establish their selectivity. In Aim 2 we will test the efficacy of the inhibitors in a reliable and novel human functional Islet beta cell line and then move to testing in primary cadaveric human pancreatic islets. The testing will utilize using our established and validated assays to test effects on insulin secretion and protection from cytokine mediated damage. Our expectation at the completion of this pilot, is to move the lead compound (s) into a novel in humanized 12-LOX mouse model of T1D that will facilitate rapid translation to clinical testing. The proposed project will provide a new way to address the high rates of adult-onset Type 1 diabetes and complications in the Veteran population.",
                "keywords": [
                    "Acceleration",
                    "Active Sites",
                    "Address",
                    "Adult",
                    "Arachidonate 12-Lipoxygenase",
                    "Arachidonate 15-Lipoxygenase",
                    "Beta Cell",
                    "Biological Assay",
                    "Biological Availability",
                    "Blood Vessels",
                    "COVID-19",
                    "Cadaver",
                    "Cardiovascular Diseases",
                    "Cell Line",
                    "Cell Physiology",
                    "Cell Survival",
                    "Cells",
                    "Cellular Assay",
                    "Characteristics",
                    "Chronic",
                    "Computer Models",
                    "Data",
                    "Databases",
                    "Death Rate",
                    "Derivation procedure",
                    "Development",
                    "Diabetes Mellitus",
                    "Disease Progression",
                    "Docking",
                    "Enzymes",
                    "Generations",
                    "Genetic",
                    "Goals",
                    "Health",
                    "Hematology",
                    "Human",
                    "Immune",
                    "In Vitro",
                    "Individual",
                    "Inflammatory",
                    "Injury",
                    "Insulin Resistance",
                    "Insulin-Dependent Diabetes Mellitus",
                    "Islet Cell",
                    "Islets of Langerhans",
                    "Isoenzymes",
                    "Kidney Diseases",
                    "LOX gene",
                    "Laboratories",
                    "Lead",
                    "Legal patent",
                    "Licensing",
                    "Lipids",
                    "Lipoxygenase Inhibitors",
                    "Machine Learning",
                    "Macrophage",
                    "Macrophage Activation",
                    "Measures",
                    "Mediating",
                    "Medical",
                    "Methods",
                    "Modeling",
                    "Modification",
                    "Neuropathy",
                    "Newly Diagnosed",
                    "Non-Insulin-Dependent Diabetes Mellitus",
                    "Obesity",
                    "Oral",
                    "Pathway interactions",
                    "Pharmaceutical Chemistry",
                    "Phase",
                    "Phase II Clinical Trials",
                    "Population",
                    "Proteins",
                    "Retinal Diseases",
                    "Safety",
                    "Site",
                    "Solubility",
                    "Structure of beta Cell of islet",
                    "Testing",
                    "Translations",
                    "Veterans",
                    "blood glucose regulation",
                    "cell injury",
                    "cytokine",
                    "design",
                    "diabetic",
                    "disability",
                    "efficacy testing",
                    "endoplasmic reticulum stress",
                    "expectation",
                    "improved",
                    "in vivo",
                    "in vivo evaluation",
                    "inhibitor",
                    "insulin dependent diabetes mellitus onset",
                    "insulin secretion",
                    "insulin signaling",
                    "intravenous administration",
                    "islet",
                    "islet cell antibody",
                    "military veteran",
                    "mouse model",
                    "non-diabetic",
                    "novel",
                    "novel therapeutics",
                    "post SARS-CoV-2 infection",
                    "pre-clinical",
                    "prevent",
                    "programs",
                    "research clinical testing",
                    "safety testing",
                    "screening",
                    "small molecule inhibitor",
                    "type I and type II diabetes"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "15678",
            "attributes": {
                "award_id": "1I01BX006894-01",
                "title": "NCOA7 deficiency worsens brain damage after stroke",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2025-04-01",
                "end_date": "2029-03-31",
                "award_amount": null,
                "principal_investigator": {
                    "id": 32523,
                    "first_name": "Dandan",
                    "last_name": "Sun",
                    "orcid": "",
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1477,
                    "ror": "https://ror.org/05eq41471",
                    "name": "Veterans Health Administration",
                    "address": "",
                    "city": "",
                    "state": "MI",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Background and Innovation: Lysosomes (with an acidic milieu of pH around 4.5) contain numerous acidic hydrolases for maintaining cellular homeostasis via the degradation of unwanted cellular components. NCOA7 (nuclear receptor coactivator 7), a member of the Tre2/Bub2/Cdc16 (TBC), lysin motif (LysM), domain catalytic (TLDc) protein family, was initially implicated in the oxidative stress as oxidation resistance proteins. However, new research demonstrates that NCOA7 directly binds and modulates vacuolar H+- ATPase (V-ATPase) assembly and activity to control endolysosomal acidification. Our pilot data from SNP- edited, human stem cell-derived endothelial cells have demonstrated that allele-specific binding of the inflammatory transcription factor NF-κB to a common intronic variant SNP rs11154337 in NCOA7 controls gene expression. Namely, we found that a C/C genotype, present in ~25% of the population, promoted lower NCOA7 expression and less lysosomal acidification (Prelim Data). Global Ncoa7 transgenic knockout mice (Ncoa7-/-, KO) are viable up to 18 months of age, with comparable gross brain structure to wild-type littermate (WT). However, upon ischemic stroke, compared to WT mice, we found that Ncoa7 KO mice exhibited worsened ischemic stroke outcomes (higher mortality, worsened blood-brain barrier impairment, increased astrogliosis and microglial activation, and abnormal accumulation of myelin basic protein, MBP) (Prelim Data). Whether the above worsened ischemic stroke outcomes resulted from V-ATPase dysfunction and lysosomal de-acidification remains unknown. In this proposal, we will test our hypotheses: 1). NCOA7 plays an important role in V-ATPase activity and lysosomal function in stroke brain in a cell-specific manner; 2). NCOA7 deficient in neurons and in oligodendrocytes drives lysosomal dysfunction and oxysterol/bile acid- specific inflammation, as well as abnormal cholesterol and MBP accumulation; 3). Post-stroke administration of NCOA7 activator Compound 958 will stimulate NCOA7 activity and reduce stroke brain damage. Significance and Impact to Veterans Healthcare: Cardiovascular diseases such as hypertension and pre- hypertension are common in active US military personnel. Moreover, post-traumatic stress disorder is associated with different cardiovascular and cerebrovascular diseases in older veterans. Collectively, these are well-established risk factors for stroke. The goal of this proposal is to study cellular mechanisms underlying the worsened ischemic stroke outcomes in NCOA7 deficient conditions and to determine whether pharmacological stimulation of NCOA7 is a novel therapeutic strategy for improving acute ischemic stroke outcomes. Therefore, our proposal is closely relevant to Veterans and the VA mission. Path to translation/implementation: completion of this study will directly address our knowledge gap about role of NCOA7 in regulating lysosome function and cholesterol metabolism in the stroke brains. To explore pharmacological tools, utilizing computational modeling, we developed a novel small molecule activator of NCOA7, Compound 958, which reduced pulmonary endothelial immunoactivation and robustly improved survival of a mouse model of acute COVID-19 (Prelim Data). Our findings from this study will reveal potentials of NCOA7 as a therapeutic target for attenuating V-ATPase dysfunction in stroke brain, and efficacy of NCOA7 activator Compound 958 in stroke therapy.",
                "keywords": [
                    "Acute",
                    "Address",
                    "Age Months",
                    "Alleles",
                    "Axon",
                    "Bile Acids",
                    "Binding",
                    "Blood - brain barrier anatomy",
                    "Blood Vessels",
                    "Brain",
                    "Brain Diseases",
                    "Brain Injuries",
                    "Cardiovascular Diseases",
                    "Catalytic Domain",
                    "Cause of Death",
                    "Cells",
                    "Cerebral Ischemia",
                    "Cerebrovascular Disorders",
                    "Cholesterol",
                    "Cholesterol Homeostasis",
                    "Computer Models",
                    "Data",
                    "Demyelinations",
                    "Drug Kinetics",
                    "Endothelial Cells",
                    "Endothelium",
                    "Endowment",
                    "Exhibits",
                    "Functional disorder",
                    "Gene Expression",
                    "Generations",
                    "Genotype",
                    "Goals",
                    "Health Care",
                    "Heterozygote",
                    "Homeostasis",
                    "Hydrolase",
                    "Hydrolysis",
                    "Hydroxylation",
                    "Hypertension",
                    "Impairment",
                    "Inflammation",
                    "Inflammatory",
                    "Institute of Medicine (U.S.)",
                    "Ischemic Stroke",
                    "Knockout Mice",
                    "Knowledge",
                    "Lung",
                    "Lysosomes",
                    "Medicine",
                    "Military Personnel",
                    "Mission",
                    "Mus",
                    "Myelin Basic Proteins",
                    "Nerve Degeneration",
                    "Neuroglia",
                    "Neurological outcome",
                    "Neurons",
                    "Nuclear Receptors",
                    "Oligodendroglia",
                    "Oxidative Stress",
                    "Pathogenesis",
                    "Play",
                    "Population",
                    "Post-Traumatic Stress Disorders",
                    "Production",
                    "Protein Family",
                    "Proteins",
                    "Pulmonary Hypertension",
                    "Recovery",
                    "Research",
                    "Resistance",
                    "Risk Factors",
                    "Role",
                    "Scientist",
                    "Sterols",
                    "Stroke",
                    "Structure",
                    "Testing",
                    "Transgenic Organisms",
                    "Translations",
                    "USP6 gene",
                    "Variant",
                    "Vascular Diseases",
                    "Veterans",
                    "acute COVID-19",
                    "astrogliosis",
                    "career",
                    "cholesterol trafficking",
                    "design",
                    "efficacy evaluation",
                    "glial activation",
                    "human stem cell-derived",
                    "improved",
                    "innovation",
                    "lysin",
                    "member",
                    "mortality",
                    "mouse model",
                    "neuron loss",
                    "novel",
                    "novel therapeutic intervention",
                    "oxidation",
                    "pharmacologic",
                    "post stroke",
                    "prehypertension",
                    "professor",
                    "small molecule",
                    "stroke outcome",
                    "stroke recovery",
                    "stroke therapy",
                    "therapeutic target",
                    "tool",
                    "transcription factor",
                    "vacuolar H+-ATPase",
                    "white matter"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "15803",
            "attributes": {
                "award_id": "1I01HX003797-01A3",
                "title": "Evaluating Veterans' Reproductive Healthcare Access, Quality and Outcomes in a Changing Landscape (EVOLVE)",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2025-07-01",
                "end_date": "2029-06-30",
                "award_amount": null,
                "principal_investigator": {
                    "id": 32893,
                    "first_name": "Lisa Susanne",
                    "last_name": "Callegari",
                    "orcid": "",
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [
                    {
                        "id": 32894,
                        "first_name": "Deirdre A",
                        "last_name": "Quinn",
                        "orcid": "",
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "awardee_organization": {
                    "id": 2660,
                    "ror": "",
                    "name": "VA PUGET SOUND HEALTHCARE SYSTEM",
                    "address": "",
                    "city": "",
                    "state": "WA",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Background: Recent years have witnessed unprecedented changes in the reproductive healthcare landscape in the US, including heightened awareness of reproductive health inequities following the 2020 nationwide racial justice reckoning, barriers to access resulting from the COVID-19 pandemic, and the proliferation of state abortion restrictions and bans following the 2022 Dobbs v Jackson Supreme Court decision. Today, access to high-quality, equitable contraceptive care has never been more vital for Veterans, who face elevated risks of poor outcomes from unintended pregnancy due to high rates of health comorbidities and psychosocial risks. The Examining Contraceptive Use and Unmet Need in Veterans (ECUUN) survey fielded in 2014-16 by study team members demonstrated high rates of unintended pregnancy and gaps in VA contraceptive access and quality, with significant disparities among Black and Latinx Veterans. While the ECUUN study helped inform VA’s reproductive health policies to date, updated data are urgently needed to capture VA’s progress in addressing disparities over time as well as its ability to meet Veterans’ needs in today’s shifted landscape. Significance: This study will generate timely quantitative and qualitative data necessary for VA as a learning health system to address gaps in access and quality and to adapt its policies and programming to meet Veterans’ changing needs. In addition, this study focuses on contraceptive counseling experiences in marginalized Veterans, for whom this care may be fraught due to the US history of reproductive oppression such as forced sterilization and policies to punish or limit reproduction in racial minority and low-income people. Findings will enable VA to respond to new White House and congressional directives related to women’s health that call for research to advance reproductive healthcare access and reduce disparities in care. Innovation & Impact: This proposal is innovative in its timeliness, use of prior data to draw novel comparisons over time, deployment of new state-of-the-art person-centered measures not yet fielded in VA such as the National Quality Forum (NQF)-endorsed Person-Centered Contraceptive Counseling (PCCC) measure, and collection of data to capture experiences of VA’s new policy to provide abortion care in select cases. Specific Aims: Aim 1: To use quantitative survey data to examine changes over time since ECUUN in contraceptive use, unintended pregnancy, and abortion, including differences by Veteran characteristics (e.g., race/ethnicity, geography). Aim 2: To use quantitative survey data to test for current disparities in novel person-centered measures (e.g., PCCC) by Veteran characteristics and characteristics of their health care. Aim 3: To contextualize Aim 1 & 2 findings, including disparities in experiences of contraceptive care and unintended pregnancy/abortion, by conducting qualitative interviews with Veterans. Methodology: This is a sequential explanatory mixed methods study beginning with a national survey of 3,600 pregnancy-capable reproductive-age Veterans who used VA primary or gynecology care in the past year. Qualitative interviews will then be conducted among Veteran survey respondents, purposively sampling at-risk subgroups (Black, Latinx, rural, residence in abortion-restrictive state) whose survey responses indicate gaps in care quality or equity. Quantitative data will inform qualitative sampling and data collection, and quantitative and qualitative data will be integrated using mixed methods analytic techniques including joint displays. Next Steps/Implementation: Next steps will include conducting a stakeholder engagement meeting with Veterans, women’s health providers, and operational partners from the Offices of Women’s Health, Health Equity, and Rural Health to share key research findings, develop strategic goals, and prioritize interventions to address disparities in contraceptive access and quality. Ultimately, this study has the potential to enhance VA’s ability to be a national leader in delivering high-quality and person-centered reproductive healthcare and to inform efforts to advance quality and equity in reproductive healthcare both within and beyond the VA.",
                "keywords": [
                    "Address",
                    "Awareness",
                    "Black race",
                    "COVID-19 pandemic",
                    "Caring",
                    "Characteristics",
                    "Clinic",
                    "Clinical",
                    "Coercion",
                    "Collaborations",
                    "Congresses",
                    "Constitution",
                    "Contraceptive Agents",
                    "Contraceptive Usage",
                    "Contraceptive methods",
                    "Counseling",
                    "Data",
                    "Data Collection",
                    "Development",
                    "Disparity",
                    "Equity",
                    "Ethnic Origin",
                    "Exclusion",
                    "Female",
                    "Geography",
                    "Goals",
                    "Gynecology",
                    "Health",
                    "Health Care",
                    "Health Personnel",
                    "Health Policy",
                    "Health system",
                    "Individual",
                    "Intention",
                    "Intervention",
                    "Interview",
                    "Investments",
                    "Involuntary Sterilization",
                    "Joints",
                    "Judgment",
                    "Justice",
                    "Latina",
                    "Latinx",
                    "Lead",
                    "Learning",
                    "Low Income Population",
                    "Low income",
                    "Measures",
                    "Medical",
                    "Medical Records",
                    "Mental Health",
                    "Methodology",
                    "Methods",
                    "Mission",
                    "Movement",
                    "Outcome",
                    "Personal Satisfaction",
                    "Persons",
                    "Policies",
                    "Populations at Risk",
                    "Pregnancy",
                    "Proliferating",
                    "Provider",
                    "Punishment",
                    "Quality of Care",
                    "Race",
                    "Recording of previous events",
                    "Reproduction",
                    "Reproductive Health",
                    "Reproductive History",
                    "Research",
                    "Respondent",
                    "Risk",
                    "Rural",
                    "Rural Health",
                    "Sampling",
                    "Services",
                    "Subgroup",
                    "Supreme Court Decisions",
                    "Surveys",
                    "Techniques",
                    "Testing",
                    "Time",
                    "Trust",
                    "United States Department of Veterans Affairs",
                    "Update",
                    "Veterans",
                    "Voice",
                    "Women's Health",
                    "abortion",
                    "access disparities",
                    "analytical method",
                    "comorbidity",
                    "disparity reduction",
                    "experience",
                    "field survey",
                    "gaps in access",
                    "gender minority group",
                    "health care availability",
                    "health care disparity",
                    "health care settings",
                    "health equity",
                    "health inequalities",
                    "innovation",
                    "marginalization",
                    "marginalized population",
                    "medical vulnerability",
                    "meetings",
                    "member",
                    "novel",
                    "patient oriented",
                    "people of color",
                    "person centered",
                    "preference",
                    "pregnancy related death",
                    "prevent",
                    "primary care provider",
                    "psychosocial",
                    "racial disparity",
                    "racial minority",
                    "reproductive",
                    "reproductive age",
                    "residence",
                    "response",
                    "rural area",
                    "rurality",
                    "sample collection",
                    "sexual minority group",
                    "sexual trauma",
                    "social",
                    "unintended pregnancy"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "15810",
            "attributes": {
                "award_id": "1I01CX002988-01",
                "title": "Long-term Cardiometabolic Disease in COVID-19",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2025-10-01",
                "end_date": "2029-09-30",
                "award_amount": null,
                "principal_investigator": {
                    "id": 44213,
                    "first_name": "Ziyad",
                    "last_name": "Al-Aly",
                    "orcid": "",
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 3364,
                    "ror": "",
                    "name": "ST. LOUIS VA MEDICAL CENTER",
                    "address": "",
                    "city": "",
                    "state": "MO",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Background: People with COVID-19 have increased risk of death and cardiometabolic disease including cardiovascular disease, diabetes mellitus, dyslipidemia and kidney disease. However, the evidence base is limited in 3 key aspects: (1) Existing studies have characterized the risks of adverse outcomes associated with earlier variants of SARS-CoV-2 and have limited follow-up. (2) It is not clear whether an annual vaccination for COVID-19 beyond the third dose reduces risk of adverse events. (3) Comparative analyses of COVID-19 vs. influenza are helpful to benchmarking risks but are only available for earlier variants and for limited follow up. Significance/Impact: Our proposal aims to answer key questions that are critical to guiding public health policy – including 1) characterizing short- and long-term risks of old, new and yet to emerge variants and subvariants of SARS-CoV-2 (proxied by the era in which they predominate); 2) on an ongoing annual basis, evaluate the effectiveness of COVID-19 vaccines in reducing risks of adverse health outcomes; and 3) on an ongoing basis, provide a comparative assessment of COVID-19 vs seasonal influenza. The proposal is specifically designed to address several key research questions outlined in the US Government National Research Action Plan on Long Covid. The results will have direct and substantial real-world impact in informing policy and clinical care. Innovation: The proposal leverages the unique power of the VA’s large-scale electronic health records and recent methodologic innovations in causal inference and clinical epidemiology to expand the evidence base about the health effects of COVID-19 and the role of vaccines. Specific Aims: To use healthcare data from the VA to: (1) characterize the acute and long-term risks of death and cardiometabolic disease in people with COVID-19 from 2020-2029, cohorted into variant-predominant eras, versus a matched historical control; (2) evaluate the effectiveness of receipt of the COVID-19 vaccine in each year (from 2022-2029) in reducing risk adverse health outcomes in the 12 months after receipt of the vaccine; and (3) comparatively evaluate the acute and long-term risks of death and cardiometabolic disease in people hospitalized for COVID-19, cohorted into variant-predominant eras, versus those hospitalized for seasonal influenza in each influenza season (from 2020 to 2029). Methodologies: VA electronic health record data will be used to construct independent cohorts for each aim and outcome being examined. COVID-19 test results and vaccination data will be collected form the COVID-19 Shared Data Resource, VA laboratory data and Medicare data. Incident outcome definitions validated for use with EHR data will be used. Inverse probability weighing will be used to balance for individual-level patient characteristics (predefined and algorithmically selected covariates), contextual characteristics, and characteristics related to the pandemic. Censoring weights will additionally be used to address situations that may result in informative loss to follow- up. Survival and mixed effect regression models will then be used to estimate differences in risk of outcomes between the COVID-19 exposure group of interest and reference groups, and estimates will be reported as hazard ratios and adjusted incidence rates, or differences in slopes. Implementation/Next Steps: Results from this proposal will inform public health policies (e.g. vaccine policies) and clinical care. Future studies will investigate optimizing care of people with cardiometabolic disease.",
                "keywords": [
                    "2019-nCoV",
                    "Acute",
                    "Address",
                    "Algorithms",
                    "Benchmarking",
                    "COVID-19",
                    "COVID-19 impact",
                    "COVID-19 risk",
                    "COVID-19 test",
                    "COVID-19 vaccination",
                    "COVID-19 vaccine",
                    "Cardiometabolic Disease",
                    "Cardiovascular Diseases",
                    "Caring",
                    "Cessation of life",
                    "Characteristics",
                    "Data",
                    "Diabetes Mellitus",
                    "Diagnosis",
                    "Dose",
                    "Dyslipidemias",
                    "Effectiveness",
                    "Electronic Health Record",
                    "Enrollment",
                    "Equilibrium",
                    "Event",
                    "Federal Government",
                    "Future",
                    "Health",
                    "Health Care",
                    "Health Policy",
                    "Hospitalization",
                    "Incidence",
                    "Individual",
                    "Infection",
                    "Influenza",
                    "Interest Group",
                    "Kidney Diseases",
                    "Knowledge",
                    "Laboratories",
                    "Long COVID",
                    "Long-term Follow-up",
                    "Medicare",
                    "Methodology",
                    "Modeling",
                    "Outcome",
                    "Patients",
                    "Persons",
                    "Policies",
                    "Probability",
                    "Proxy",
                    "Public Health",
                    "Recording of previous events",
                    "Reporting",
                    "Research",
                    "Risk",
                    "Risk Reduction",
                    "Role",
                    "SARS-CoV-2 exposure",
                    "SARS-CoV-2 variant",
                    "Test Result",
                    "Testing",
                    "Time",
                    "United States Department of Veterans Affairs",
                    "Vaccination",
                    "Vaccines",
                    "Variant",
                    "Weight",
                    "acute COVID-19",
                    "adverse event risk",
                    "adverse outcome",
                    "cardiometabolic risk",
                    "cardiometabolism",
                    "clinical care",
                    "clinical epidemiology",
                    "cohort",
                    "comparative",
                    "data sharing networks",
                    "design",
                    "effectiveness evaluation",
                    "evidence base",
                    "follow-up",
                    "hazard",
                    "innovation",
                    "mortality risk",
                    "pandemic disease",
                    "seasonal influenza"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "14192",
            "attributes": {
                "award_id": "5I01HX003576-02",
                "title": "Impact of COVID-19 on Continuity of Care for Veterans on Antipsychotic Medications",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2022-11-01",
                "end_date": "2024-10-31",
                "award_amount": null,
                "principal_investigator": {
                    "id": 26863,
                    "first_name": "ANOUK L",
                    "last_name": "GRUBAUGH",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1782,
                    "ror": "",
                    "name": "RALPH H JOHNSON VA MEDICAL CENTER",
                    "address": "",
                    "city": "",
                    "state": "SC",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Background: Severe mental illnesses are consistently ranked as some of the most debilitating health conditions worldwide due to their early age of onset, chronicity, and impact on functioning. Fortunately, a number of antipsychotic medications have been found to be effective for managing the symptoms of severe mental illness (SMI) and for preventing relapse and rehospitalization. Despite their efficacy, treatment non-compliance for individuals on these medications is high due to a number of factors including poor insight into illness, negative attitudes about medication, and medication related side effects. Further complicating care and outcomes for this clinical population, providers must maintain close oversight of patients on antipsychotics due to the impact of these medications on metabolic and cardiac functioning which confer an increased risk of obesity, diabetes, heart problems, and other chronic illnesses. This oversight includes regular monitoring of weight, blood pressure, fasting blood glucose, and lipid levels. Additionally, clozapine, indicated for treatment-resistant schizophrenia, requires weekly-to-monthly monitoring of absolute neutrophil counts to prevent potentially fatal clozapine- induced agranulocytosis. Significance: The proposed project has significant and immediate relevance to Veterans and the VHA in that it seeks to better understand if and to what extent COVID-19 related care disruptions impacted care and outcomes for Veterans with SMI prescribed antipsychotic medications. Given pre- existing challenges in the treatment of this Veteran population, this is an important area of inquiry as well as one for which little is known. Added strengths of the proposed study include the use of a mixed methods approach that includes national level data from multiple sources. Aside from addressing a critical knowledge gap, the proposed study targets what is unarguably one of the most vulnerable patient populations within the VA and other healthcare systems—patients with SMI prescribed antipsychotic medications. Specific Aims: Aim 1: To assess the impact of COVID-19 related care disruptions on healthcare use and outcomes for Veterans on antipsychotic medications using robust statistical methods and national level data; Aim 2: To assess whether the impact of COVID-19 related care disruptions differ by race/ethnicity, gender, age, and rural/urban status using national level data; Aim 3: To conduct thematic interviews with provider and patient stakeholder groups at the national level to better understand COVID-19 related care disruptions. Provider stakeholders (e.g., psychiatrists, advanced nurse practitioners) will be interviewed to better understand COVID-19 related changes in practice behaviors, the perceived impact of these changes on care continuity and outcomes, and to solicit suggestions to mitigate the impact of interrupted care in the future; Veterans prescribed antipsychotic medication prescriptions in the pre COVID-19 window will be interviewed to better understand the impact of COVID-19 related care disruptions on treatment seeking behaviors, obstacles encountered with regard to access, and to explore other factors potentially impacting outcomes in this patient group. Methodology: The proposed study will employ a mixed-methods (quantitative/qualitative) approach. For Aims 1 & 2 we will employ retrospective, observational analyses using a national cohort of Veterans (N>250,000) with an ICD-CM-10 diagnostic code for schizophrenia or bipolar disorder prescribed a first-generation or second-generation antipsychotic [1/19-12/21]. Veterans of all ages, genders, racial groups, military eras will be included in the cohort. Aim 3 will involve individual thematic interviews with provider (n=35-45) and patient stakeholders (n=50-60). Next Steps/Implementation: Findings from this 2-year project will be of immediate relevance and impact for local, regional, and national level administrators and mental health providers as well as the VA Office of Mental Health and Suicide Prevention and VA Pharmacy Benefits Management Services. Collectively, data from this project will serve to identify potential strategies to further mitigate the impact of COVID-19 on the care and outcomes of Veterans with SMI as well as prepare for future public health and/or other national emergencies.",
                "keywords": [
                    "Address",
                    "Adherence",
                    "Administrator",
                    "Admission activity",
                    "Age",
                    "Age of Onset",
                    "Agranulocytosis",
                    "Antipsychotic Agents",
                    "Area",
                    "Attitude",
                    "Behavior",
                    "Bipolar Disorder",
                    "Blood Glucose",
                    "Blood Pressure",
                    "COVID-19",
                    "COVID-19 impact",
                    "Caring",
                    "Chronic",
                    "Chronic Disease",
                    "Clinical",
                    "Clozapine",
                    "Code",
                    "Continuity of Patient Care",
                    "Data",
                    "Data Sources",
                    "Diabetes Mellitus",
                    "Diagnostic",
                    "Disease",
                    "Drug Prescriptions",
                    "Emergency Care",
                    "Emergency Situation",
                    "Ethnic Origin",
                    "Event",
                    "Fasting",
                    "Future",
                    "Gender",
                    "Generations",
                    "Guidelines",
                    "Health",
                    "Health Personnel",
                    "Healthcare",
                    "Healthcare Systems",
                    "Heart",
                    "Heart Diseases",
                    "Individual",
                    "Inpatients",
                    "Interruption",
                    "Interview",
                    "Knowledge",
                    "Lipids",
                    "Malignant Neoplasms",
                    "Mental Health",
                    "Mental disorders",
                    "Metabolic",
                    "Methodology",
                    "Methods",
                    "Military Personnel",
                    "Monitor",
                    "Nurse Practitioners",
                    "Outcome",
                    "Outpatients",
                    "Patients",
                    "Pharmaceutical Preparations",
                    "Pharmacists",
                    "Population",
                    "Provider",
                    "Psychiatrist",
                    "Public Health",
                    "Race",
                    "Research Design",
                    "Resistance",
                    "Rural",
                    "Safety",
                    "Schizophrenia",
                    "Services",
                    "Statistical Methods",
                    "Suggestion",
                    "Suicide",
                    "Suicide prevention",
                    "System",
                    "Testing",
                    "Veterans",
                    "Visit",
                    "Weight",
                    "Woman",
                    "care outcomes",
                    "cohort",
                    "cost",
                    "economic impact",
                    "ethnic minority",
                    "experience",
                    "health care availability",
                    "health care delivery",
                    "health care service utilization",
                    "heart function",
                    "hospital readmission",
                    "insight",
                    "military veteran",
                    "mortality",
                    "multiple data sources",
                    "neutrophil",
                    "non-compliance",
                    "obesity risk",
                    "patient population",
                    "pharmacy benefit",
                    "post-COVID-19",
                    "prevent",
                    "racial minority",
                    "racial population",
                    "relapse prevention",
                    "rural area",
                    "severe mental illness",
                    "side effect",
                    "symptom management",
                    "urban dwelling"
                ],
                "approved": true
            }
        }
    ],
    "meta": {
        "pagination": {
            "page": 1392,
            "pages": 1442,
            "count": 14420
        }
    }
}